drugset / Trial / NCT03528564
Hemoglobin Optimization to Prevent Transfusion and Adverse Events in Perioperative Patients With Iron Restricted Anemia
RandomizedParallel-groupDouble-blindTreatment
Summary
The HOPE-Hb trial is a phase II study to determine the feasibility and impact of a combination treatment (intravenous iron plus erythropoietin) versus intravenous iron treatment alone on preoperative hemoglobin concentration before hip or knee arthroplasty.
Timeline
- Start
- 2019-07-01
- Primary completion
- 2021-05-31
- Completion
- 2021-05-31
Outcome
Outcome not reported
Stopped: “The primary reasoning is that we were unable to demonstrate feasibility, prior to and because of the impact of COVID on our research programs.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Iron sucrose | Unknown | 900 mg | Intravenous |
| Subject | epoetin alfa | Protein / enzyme biologic | 40000 iu | Subcutaneous |